Overview of Neometrin

Property	Description
Active ingredient	Ergometrine (Ergonovine)
Form	Solution for Injection, Oral Tablet
Pharmacological class	Ergot Alkaloid, Uterotonic Agent
Common use	Control of excessive bleeding
Origin	Semi-synthetic compound

Neometrin is a prescription medication whose active substance is Ergometrine (also known as Ergonovine), which is fundamentally classified as a potent uterotonic agent and an amine ergot alkaloid. This drug is specifically defined by its ability to stimulate the smooth muscle tissue of the uterus to achieve strong, coordinated contraction, an action clinically recognized for its role in supporting maternal health.

What is Neometrin and What is its Classification?

The active compound, Ergometrine, is a semi-synthetic substance derived from the natural ergot alkaloids. As an ergot alkaloid, its structure allows it to interact with specific receptors in smooth muscle, particularly those that regulate muscle tone. Pharmacological information confirms its classification as a specialized uterotonic agent, which distinguishes it from other pain or infection treatments. This confirms its dedicated function is to increase the contractile force of the uterine wall.

Composition and Available Forms of Neometrin

Neometrin is a single-ingredient product, typically utilizing the stable salt Ergometrine maleate. A key feature is its availability in two distinct dosage forms: a solution for injection and oral tablets. The solution is prepared in an aqueous base for parenteral administration, facilitating an immediate pharmacological response. Conversely, the tablet form allows for oral intake, which is often used for sustained, non-acute management. The preparation thus encompasses both rapid-response and sustained-use formats.

General Purpose: How Neometrin Works at a Basic Level

The general purpose of Neometrin is to control excessive bleeding by maximizing the uterus's capacity to contract and self-seal blood vessels. This effect is used in situations that require immediate intervention to manage blood flow. Its potent oxytocic action causes a sustained and strong uterine contraction, simultaneously inducing vasoconstriction (narrowing) of the blood vessels within the muscular wall. This unique mechanism generates the necessary physical compression and circulatory restriction required to rapidly achieve hemostasis, serving as the medicine's fundamental therapeutic benefit.

Regulatory References

What side effects are possible with Neometrin?

Possible Side Effects and Safety Information

The safety profile of Neometrin (Neomycin Sulfate) is defined by the potential for serious, permanent toxic effects, as highlighted in regulatory warnings.

Serious Adverse Reactions and Organ Toxicity

Regulatory warnings emphasize the risk of organ toxicity that can occur due to systemic absorption, even when administered orally. Clinically significant risks include:

Ototoxicity: Damage to the inner ear that can result in permanent, bilateral hearing loss and vestibular toxicity (balance issues).
Nephrotoxicity: Damage to the kidneys, potentially leading to renal impairment.
Neurotoxicity: Can manifest as neuromuscular blockade, leading to muscle weakness and potentially fatal respiratory paralysis.

Common Adverse Reactions

The most frequent and expected adverse reactions are primarily related to the gastrointestinal system:

Nausea and Vomiting
Diarrhea
Irritation or soreness of the mouth or rectal area

Safety Restrictions and Monitoring

To manage these risks, regulatory documents establish strict limitations:

Mandatory Monitoring: Regular monitoring of kidney function and serial audiometric tests are required, especially for patients at high risk.
Drug Interactions: The use of Neometrin concurrently or sequentially with other known nephrotoxic or neurotoxic medications (including certain other antibiotics and diuretics) is restricted.

Population-Specific Safety

The risk of toxicity is heightened in certain populations, as documented in regulatory labeling:

Impaired Renal Function: Patients with reduced kidney function have a higher risk of ototoxicity and nephrotoxicity.
Elderly and Neonates: These groups are more susceptible to the toxic effects on the hearing and kidneys.
Pregnancy: The medication is classified with known risk, as reports show potential for fetal hearing loss.

Note: Risk of toxicity, particularly ototoxicity, increases with higher doses and longer duration of therapy.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Neometrin (Ergometrine) is classified in official regulatory documents as potentially life-threatening due to its potent systemic toxicity, which necessitates immediate and urgent medical intervention.

Documented Manifestations and Severe Outcomes

Overdose presentations are primarily linked to intense vascular constriction and central nervous system (CNS) effects. Documented manifestations include gastrointestinal distress (nausea, vomiting, severe abdominal pain), severe headaches, confusion, muscle cramps, and pronounced elevation of blood pressure (hypertension).

Life-threatening outcomes explicitly documented in regulatory sources are seizures, cerebral hemorrhage, respiratory depression or arrest, and profound peripheral vasoconstriction. This vasoconstriction can result in localized numbness, tingling, or coldness in the extremities, a sign of severe peripheral ischemia. Special consideration is noted for patients with pre-existing vascular disease or hepatic/renal impairment, who may have increased susceptibility to severity.

Required Emergency Actions

Due to the risk of severe complications, official guidance mandates that you seek immediate medical attention or contact emergency services instantly upon any suspicion of overdose. Management is uniformly described as symptomatic and supportive treatment provided in a hospital setting with continuous cardiovascular and respiratory function monitoring. There is no specific antidote known, but supportive care often includes administering peripheral vasodilators to manage severe arteriospasm.

Therapeutic Uses of Neometrin

What Neometrin Treats: Main Uses and Benefits

Neometrin is a prescription medication utilized to help manage certain gynecological and lower urinary tract symptoms that arise from specific infections. It is indicated for use in managing conditions such as bacterial vaginitis, trichomoniasis, and giardiasis. The common therapeutic scenarios involve supporting the treatment of these infections to assist in relieving uncomfortable associated symptoms, including vaginal discharge, odor, pain, and itching.

The primary benefit for the patient is the support of symptom relief and the management of the underlying infection. The approved uses for this medicine are documented and established for these specific therapeutic scenarios.

“Neometrin is a medication used to help provide relief associated with certain common infections.”

Quick Fact: Relief for Vaginal Symptoms

Eligibility and Restrictions for Use

The eligibility to use this medicine is strictly defined by regulatory documents, which list several groups for whom use is prohibited or restricted. The information below is based on the official labeling for metronidazole, the active component suggested by the product name.

Populations for Whom Use Is Prohibited (Contraindicated)

The medicine is formally contraindicated for any patient with a documented history of hypersensitivity or allergic reaction to metronidazole or other related nitroimidazole derivatives. Use is also prohibited in patients who have taken disulfiram within the last two weeks (14 days), and in patients with a specific genetic disorder called Cockayne syndrome due to the risk of severe liver failure.

Restricted or Cautionary Use

Pregnancy and Lactation: The use of the medicine is contraindicated during the first trimester of pregnancy when treating trichomoniasis. For other uses, it may be restricted based on risk assessment.
Organ Impairment: Patients with severe hepatic impairment (liver disease) must receive a reduced dose. Those with severe renal impairment (kidney disease) or certain central nervous system disorders require close patient monitoring.
Alcohol: Consumption of alcohol or products containing propylene glycol is strictly prohibited during treatment and for at least three days after the final dose.

What should I know about interactions with other medicines?

Neometrin, whose active ingredient is Ergometrine, has an interaction profile defined by both its metabolic pathway and its intrinsic vasoconstrictive and uterotonic properties, as documented in official regulatory labeling.

Contraindicated and Restricted Combinations

Co-administration with strong CYP3A4 inhibitors is formally contraindicated due to the risk of significantly increasing Ergometrine exposure, which can lead to severe or life-threatening vasospasm and ischemia. Interacting examples explicitly listed in regulatory documents include macrolide antibiotics (e.g., Erythromycin, Clarithromycin) and azole antifungals (e.g., Ketoconazole, Itraconazole).

Pharmacokinetic and Pharmacodynamic Interactions

The primary mechanistic basis for pharmacokinetic interactions is the inhibition of CYP3A4-mediated clearance, leading to increased drug concentration (AUC). Conversely, CYP3A4 inducers (e.g., Rifampicin, Nevirapine) are documented to reduce the drug's clinical effect by accelerating its metabolism.

Pharmacodynamic interactions require caution or restriction when used with:

Other Ergot Alkaloids and Triptans (e.g., Sumatriptan): Risk of additive vasoconstriction and increased arterial spasm.
Vasoconstrictors/Sympathomimetics: Enhanced pressor effects, risking severe hypertension.
Prostaglandins and their analogues: Potentiation of the uterotonic action.

Mechanism of Action

How Neometrin Works: Mechanism of Action

Dual Inhibition of Microbial Cell Survival

Neometrin functions by simultaneously targeting two distinct microbial processes: protein synthesis and DNA integrity. One component binds irreversibly to the bacterial 30S ribosomal subunit , resulting in faulty protein production. The second component is a prodrug that is reductively activated by the microbe to create highly reactive free radicals that damage and fragment its DNA. This dual molecular mechanism initiates a cell death cascade within susceptible organisms.

Environmentally Dependent Cytotoxic Cascade

This mechanism is characterized by an environmentally dependent cascade; one component requires anaerobic (low-oxygen) conditions within the microbe to become biologically active and cytotoxic. This dual action encompasses different microbial metabolic types. The resulting physiological consequence is the elimination of susceptible pathogens. The halting of microbial toxin production and associated signaling influences local tissue response.

Dosage and Administration Information

How to Use Neometrin

Neometrin (Ergometrine or Methylergonovine) is administered according to a specific, two-part established protocol, ensuring its use aligns with the acute and follow-up needs after childbirth. This medicine is available as a solution for injection and as an oral tablet for postpartum management.

Administration Routes and Initial Dosing

The most common method for rapid response is an Intramuscular (IM) injection, utilizing the standard starting dose of 0.2 mg (or 200 micrograms). This parenteral route is strictly administered after the delivery of the anterior shoulder or the placenta. The Intravenous (IV) route is generally reserved for emergency situations, and if used, the injection must be given slowly over no less than 60 seconds to mitigate the risk of rapid systemic effects. For acute control, the IM dose may be repeated every 2 to 4 hours, with a specified limit on the total number of doses that should be given.

Sustained Management and Duration

Following the initial acute parenteral treatment, the drug transitions to the oral tablet form, typically 0.2 mg per tablet, taken three or four times daily. This oral regimen is explicitly intended for short-term use, with the course of treatment generally lasting no longer than one week postpartum.

Official Use Constraints

Patients with severe renal or hepatic impairment are generally excluded from use. Dosing for older adults requires caution, with clinical guidance suggesting a starting dose at the lower end of the range. If an oral dose is missed, standard instructions advise the individual to skip the missed dose if it is near the next scheduled time and avoid doubling the dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Neometrin

Neometrin (Ergometrine) was studied for use in acute maternal health settings in research contexts involving conditions associated with excessive bleeding. The available research stems from large-scale clinical trials and comprehensive summaries, which was evaluated in research contexts involving acute, immediate needs rather than long-term or chronic conditions. This summary describes the structure of the evidence without giving advice on its use.

Evidence for Managing Excessive Postpartum Bleeding

The research explored for acute blood management is generally founded on Randomized Controlled Trials (RCTs) and Systematic Reviews, evaluating women who delivered vaginally and, in some research, those who had a Caesarean section. Studies examined how blood loss evolved, tracking specific volumes (e.g., 500 mL or 1000 mL), and highlighted changes measured during the study period relating to whether additional treatments were needed to manage bleeding.

What Research Studies Examined

Research examined outcomes related to systemic or functional imbalance that may follow periods of severe blood loss. The outcomes studied were specifically focused on acute medical metrics. Studies monitored outcomes such as the percentage of participants who required a blood transfusion, an outcome monitoring physiological strain or stress. The evidence base often describes patterns where Neometrin was observed in a combination therapy; where it was studied with another medication, such as Oxytocin, rather than alone.

Long-Term Monitoring and Follow-up in Studies

The follow-up durations for many critical studies were limited to the immediate post-delivery phase, typically lasting up to 24 hours. While research exploring short-term symptom changes is common, long-term effects are not fully established. Some studies did include follow-up extending to around six weeks postpartum to observe general health and functional status.

Evidence in Specific Patient Populations

Data for certain groups remain insufficient. The research examined certain patient groups by sorting them based on their pre-existing risk factors for excessive bleeding, covering those categorized as high-risk and low-risk populations. Data for groups where research examined outcomes related to cardiovascular health are still emerging or are limited, as findings describe patterns related to subgroups where data remain insufficient.

Overall Consistency and Research Gaps

The overall evidence quality is typically rated as High or Moderate in certainty for the acute outcomes was studied for, largely due to the large number of RCTs and high-level reviews. Key limitations include that comparative evidence is lacking when looking at Neometrin as a single agent versus other single agents. The evidence contributes to understanding acute symptom patterns but not long-term stability.

Frequently Asked Questions (FAQ)

Common questions about Neometrin (FAQ)

Q: How quickly does Neometrin start to work after I begin taking it?

A: According to official product information, the medicine starts working at different speeds depending on the route of administration. The labeling describes the typical onset of action for an intramuscular (IM) injection as occurring within approximately 2 to 7 minutes. For the intravenous (IV) injection, which is typically reserved for emergencies, the effect is described as being more rapid, occurring within about 40 seconds to one minute.

Q: How long does Neometrin stay in your system after stopping treatment?

A: The drug is designed to be relatively short-acting. Official pharmacology descriptions state that the plasma half-life—the time it takes for half the medicine to be eliminated—is generally described as being between 30 and 120 minutes. This indicates a relatively rapid decrease in the concentration of the active ingredient in the body.

Q: Are there different strengths or versions of Neometrin?

A: Regulatory documents refer to different versions of Neometrin. It is available as an oral tablet for sustained use and a solution for injection for initial, rapid response. The specific dosage strength used depends on the medical need and the route of administration, which includes a standard 0.2 mg tablet.

Q: What happens if I forget to take a dose of Neometrin?

A: Regulatory guidance for the oral tablet form addresses this. It advises that if a dose is missed and it is near the next scheduled time, the missed dose should be skipped entirely. The instructions advise resuming the regular schedule and state that the dose should not be doubled to compensate for the missed one.

Q: Is Neometrin taken long-term or only for a short time?

A: This medicine is explicitly intended for short-term use related to acute needs after childbirth. The oral tablet regimen, which typically follows the initial injection, is generally described in official labeling as lasting up to one week postpartum.

Q: Do older adults react differently to Neometrin?

A: Caution is advised for use in older adults. Regulatory guidance indicates a greater likelihood of age-related conditions, such as those affecting the kidneys, liver, or heart, which may require medical consideration. Official documents note that a lower starting dose may be recommended in this population.

Q: Can I use Neometrin if I am allergic to penicillin?

A: Official warnings state the medicine is contraindicated (prohibited) for those with a history of hypersensitivity or allergy specifically to ergometrine or other medicines in the ergot alkaloid class. Cross-reactivity with penicillin is not specifically addressed in the official labeling.

Q: Are headaches a frequent side effect of Neometrin?

A: Official labeling documents list headache among the frequently reported adverse reactions associated with the use of Neometrin. Other common effects reported include abdominal pain and, in some cases, increased blood pressure.

Q: What is the duration of treatment generally described for Neometrin?

A: The total duration of treatment is described as short-term. It typically involves initial injection doses followed by an oral tablet regimen. The oral portion of the treatment course is generally described as lasting up to one week postpartum.

Q: Can Neometrin be used by children or teenagers?

A: Official regulatory documents indicate that appropriate studies on the relationship of age to the drug's effects have not been performed in the pediatric population (children and teenagers). Consequently, the safety and efficacy of the medicine have not been established in these age groups.

Q: Does Neometrin cause you to feel tired or dizzy?

A: Official labeling lists dizziness among the rarely observed reactions associated with the medicine. Other central nervous system effects such as drowsiness or confusion are also mentioned as rare side effects that have been reported.

Q: Does Neometrin expire, and how long is it good for?

A: The expiration date is determined by the manufacturer and is printed on the label. The stability instructions for the injection solution (liquid) specifically state that if it is stored outside the recommended refrigeration temperature, it may be kept at controlled room temperature for a maximum of 12 weeks before it must be discarded.

Q: Is Neometrin available over the counter, or is it prescription-only?

A: The active ingredient, Ergometrine, is listed in authoritative regulatory and labeling documents as a medicine that is prescription-only for its indicated use in managing bleeding after childbirth.

Q: Are there any restrictions on driving while taking Neometrin?

A: Official patient information advises that side effects such as dizziness, visual changes, and headache may occur. These effects may potentially affect the ability to drive or operate machinery. Awareness of this possibility is noted in official documents.

Q: Can Neometrin be used for something other than its main approved purpose?

A: Official documents restrict the use of this medicine to its approved indications only. The use of the medicine is defined by its official indication, which is the prevention and treatment of excessive bleeding from the uterus after childbirth.

Q: Do official documents mention any risk of dependency with Neometrin?

A: Official regulatory reviews, including those for controlled substances, do not list the drug as a scheduled substance. The available regulatory documentation does not mention a risk of dependency or abuse potential associated with Neometrin.

Q: How can I tell if Neometrin is working as expected?

A: The medicine's fundamental therapeutic goal, as described in official documents, is the management of excessive uterine bleeding. Its pharmacological effect is to cause strong uterine contractions and constriction of blood vessels within the uterus, which is intended to rapidly achieve hemostasis (stopping or slowing the bleeding).

Q: Is it possible to have an allergic reaction to Neometrin?

A: Official documents list hypersensitivity (severe allergic reaction) to the active substance or other ergot alkaloids as a formal contraindication. Symptoms associated with an allergic reaction may include difficulty breathing, severe headache, chest pain, or swelling.

Q: How common are serious side effects with Neometrin?

A: Serious side effects, such as very high blood pressure (hypertension), coronary artery spasm, and cerebral (brain) vasospasm, are reported in regulatory documents as rare. The potential for serious side effects is addressed by monitoring during the treatment process.

Q: Can Neometrin interact with common cold or flu medicines?

A: Regulatory documents state that caution is necessary if the medicine is used along with sympathomimetic agents. These are a class of drugs, sometimes found in cold or flu medicines, that can increase the risk of enhanced vasoconstriction (narrowing of blood vessels) and elevated blood pressure.

Q: Are there any long-term effects associated with taking Neometrin?

A: Research evidence indicates that the follow-up period for most critical studies on this medicine was limited to the immediate post-delivery phase (typically up to 24 hours). Therefore, the long-term effects are not fully established by current research in the same way as the acute effects.

Q: Does Neometrin affect fertility?

A: Official labeling documents state that studies to assess the effect of the medicine on fertility in animals or humans have not been performed.

Q: Is Neometrin prescribed for both men and women?

A: The sole approved indication for Neometrin is the prevention and treatment of excessive bleeding from the uterus following childbirth. This medical condition is specific to women in the postpartum period, and the drug is prescribed accordingly.

Q: Are there different storage instructions for Neometrin in liquid form?

A: Official labeling specifies different instructions based on the form. The injection solution (liquid form) typically requires storage between 2 C and 8 C (refrigeration) and must be kept protected from light. The oral tablet form is generally stored at controlled room temperature.

Q: What happens if I miss more than one dose of Neometrin?

A: Official guidance is provided for missing a single oral dose (to skip it and not double up). The regulatory documents do not explicitly cover the instructions for missing multiple doses; the guidance provided applies only to a single missed oral dose.

Q: Is it common to feel nauseous while taking Neometrin?

A: Nausea is reported in regulatory documents as an adverse reaction associated with this medicine. If this symptom is experienced, it is listed alongside other potential gastrointestinal effects.

How should Neometrin be stored and disposed of?

Official Storage and Disposal Requirements

Regulatory documents define specific conditions for storing and disposing of this medication to maintain its integrity and safety. These requirements are based on official labeling, which dictates environmental controls and handling protocols.

Storage Component	Official Requirement
Temperature	Store at controlled room temperature, typically below 25°C (77°F).
Protection	Mandatory to protect from light and moisture; keep the container tightly closed.
Handling	Keep the product in its original packaging until time of use. Do not use past the labeled expiration date.
Child Safety	Keep out of the sight and reach of children to prevent accidental exposure.
Disposal Protocol	Do not flush unused medication down the toilet or pour it down a drain. Dispose of unused product in household trash after mixing it with an undesirable substance.

Neometrin